The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been ...

This move diversifies options for patients following the earlier approval of Eisai and Biogen's Leqembi in January. CVS faces ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Lecanemab (Leqembi) and donanemab (Kisunla) have both received FDA approval as amyloid-beta targeting therapies.⁷⁻⁸ Several ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Korea must embrace gender innovation to combat drug discrimination and promote equity Korean researchers urged to prioritize ...

Currently, the only two Alzheimer’s medications approved for market by the U.S. Food and Drug Administration (FDA) are ...